TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic

ONC201 was initially identified as an inducer of cell death through the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway. The compound is currently being tested in patients with hematological malignancies and solid tumors, including those of the breast. We investigated strateg...

Descripción completa

Detalles Bibliográficos
Autores principales: Ralff, Marie D., Jhaveri, Aakash, Ray, Jocelyn E., Zhou, Lanlan, Lev, Avital, Campbell, Kerry S., Dicker, David T., Ross, Eric A., El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584235/
https://www.ncbi.nlm.nih.gov/pubmed/33144917
http://dx.doi.org/10.18632/oncotarget.27773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584235/
https://www.ncbi.nlm.nih.gov/pubmed/33144917
http://dx.doi.org/10.18632/oncotarget.27773

Ejemplares similares